SS-31 (Elamipretide): Reversing Mitochondrial Aging at the Inner Membrane
SS-31 is the only compound that directly targets cardiolipin in the inner mitochondrial membrane, restoring cristae architecture and electron transport chain efficiency. Early randomised clinical data in heart failure.
Evidence strength
Level 2b
Individual cohort study
Peer-reviewed refs
3
Reading time
12 min
Key Takeaways
- SS-31 binds cardiolipin in the inner mitochondrial membrane, the only compound with this mechanism of action.
- In a randomised, placebo-controlled trial in heart failure with reduced ejection fraction, a single elamipretide infusion was safe and the highest dose reduced left ventricular volumes.
- SS-31 should precede MOTS-c in mitochondrial protocols — repair existing infrastructure before stimulating biogenesis.
- No approved for commercial use. Research peptide requiring subcutaneous injection. No long-term human safety data beyond Phase 2 trials.
The Cardiolipin Crisis of Ageing
Every cell in your body contains hundreds to thousands of mitochondria. These organelles are not static — they constantly fuse, divide, and are replaced. But their efficiency depends critically on a phospholipid that exists almost nowhere else in biology: cardiolipin.
Cardiolipin is uniquely adapted to the inner mitochondrial membrane. Its unusual four-acyl structure allows it to create the tight membrane curvature required for cristae — the folded structures that pack the electron transport chain (ETC) complexes into a dense, efficient arrangement. Cardiolipin also serves as a molecular scaffold, holding ETC Complexes I through IV in close proximity for efficient electron transfer.
With age and oxidative stress, cardiolipin undergoes progressive oxidation and degradation. The consequences cascade:
- Cristae unfold and lose their tight curvature
- ETC complexes dissociate from each other, reducing electron transfer efficiency
- Electrons leak from the chain, producing reactive oxygen species instead of ATP
- Cytochrome c — normally bound to cardiolipin — releases into the cytoplasm, triggering apoptosis
This is the structural basis of mitochondrial ageing. And until SS-31, no compound directly addressed it.
The SS-31 Mechanism
SS-31 (D-Arg-Dmt-Lys-Phe-NH₂) was designed specifically to target the inner mitochondrial membrane. Its alternating cationic-aromatic structure allows it to penetrate the mitochondrial membrane and bind directly to cardiolipin via complementary electrostatic and hydrophobic interactions.
[1]This binding produces a cascade of structural and functional restorations:
Cristae restoration: Cardiolipin stabilisation restores the membrane curvature needed for cristae formation. ETC complexes reassemble into efficient supercomplexes.
ROS reduction: By maintaining ETC complex organisation, SS-31 reduces electron leakage — the primary source of mitochondrial reactive oxygen species. This breaks the vicious cycle where ROS damages cardiolipin, which impairs the ETC, which generates more ROS.
Cytochrome c retention: Stabilised cardiolipin retains cytochrome c on the membrane, reducing pro-apoptotic signalling.
ATP restoration: Functional ETC + intact cristae = restored ATP synthesis efficiency.
Clinical Evidence: Heart Failure
The first human evidence in heart failure comes from a double-blind, placebo-controlled, ascending-dose trial in 36 patients with heart failure with reduced ejection fraction (HFrEF, ejection fraction ≤35%), who received a single 4-hour infusion of elamipretide or placebo.
[2]Heart failure patients were chosen because mitochondrial dysfunction is a primary driver of the condition. Results:
- No serious adverse events; blood pressure and heart rate remained stable
- At the highest dose, left ventricular end-diastolic volume fell by 18 mL and end-systolic volume by 14 mL versus placebo at the end of the infusion
- The changes tracked peak plasma drug levels, supporting a dose-effect relationship
This was a single-dose study measuring acute changes; it did not test exercise capacity or quality of life, and longer trials are needed to establish lasting benefit.
Skeletal Muscle and Ageing
A 2019 study in aged mice showed that 8 weeks of SS-31 treatment reversed the age-related decline in skeletal muscle maximum mitochondrial ATP production and oxidative phosphorylation coupling, reduced redox stress, and improved exercise tolerance.
[3] This study is particularly relevant for the longevity and performance use case — suggesting SS-31 can partially reverse the mitochondrial decline that underlies age-related muscle weakness and fatigue.
Why SS-31 Must Come Before MOTS-c
The sequencing principle is mechanistically important. MOTS-c (and other PGC-1α activators like exercise and PQQ) stimulates mitochondrial biogenesis — the creation of new mitochondria. But new mitochondria are assembled from components of existing mitochondria. If the existing population has degraded cardiolipin and damaged cristae, new mitochondria inherit these structural defects.
SS-31 first restores the structural integrity of existing mitochondria, establishing a healthy template. MOTS-c then drives biogenesis of new mitochondria built on that corrected template. The sequence: SS-31 at 8am, MOTS-c 2 hours later.
Practical Protocol
Subcutaneous injection, 20mg/day (or 0.25mg/kg). Once daily in the morning. 4–8 week cycles with 2-week breaks. The Mitochondrial Matrix Protocol adds MOTS-c, NMN, and PQQ for comprehensive restoration of all four layers of mitochondrial function.
Related Substances
Scientific References
- [1]Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics — British Journal of Pharmacology (2014)Oxford 5PMID 24117165
- [2]Daubert MA, Yow E, Dunn G, et al.. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide — Circulation. Heart Failure (2017)Oxford 1bPMID 29217757
- [3]Campbell MD, Duan J, Samuelson AT, et al.. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice — Free Radical Biology & Medicine (2019)Oxford 5PMID 30597195
Follow us on Google Search
Add BiohackingHub as a preferred source to see more of our research in Google results.
Related protocols
Partner with BiohackingHub
Editorial placements, sponsorships, and product features for evidence-minded brands.